Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,262
datasets available to search
ShareScore release 0.9.0
Dataset results
6,262 results for “Treatment efficacy”
The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy.
<p>Data used for the publication of a paper entitled: <strong>The within-host population dynamics of <em>Mycobacterium tuberculosis</em> vary with treatment efficacy.</strong></p> <p>The data were derived from:</p> <p>1. the deep sequencing of serial sputum samples from 12 TB patients,</p> <p>2. the deep sequencing of liquid cultures derived from the expansion of individual colonies <em>in vitro</em>,</p> <p>3. <em>In </em><em>silico</em> simulations of DNA sequencing, populations and mutagenesis.</p> <p>The analytical scripts associated with the generation of the data can be found at:</p> <p>https://github.com/swisstph/TBRU_serialTB/</p> <p><strong>Paper Abstract:</strong></p> <p><strong>Background:</strong></p> <p>Combination therapy is one of the most effective tools for limiting the emergence of drug resistance. Despite the widespread adoption of combination therapy across diseases, drug resistance rates continue to rise, leading to failing treatment regimens. The mechanisms underlying treatment failure are well studied, but the processes governing successful combination therapy are poorly understood. We addressed this question by studying the population dynamics of <em>Mycobacterium tuberculosis</em> within tuberculosis patients undergoing treatment with different combinations of antibiotics.</p> <p><strong>Results:</strong></p> <p>By combining very deep whole genome sequencing (~1,000-fold genome-wide coverage) with sequential sputum sampling, we were able to detect transient genetic diversity driven by the apparently continuous turnover of minor alleles, which could serve as the source of drug-resistant bacteria. However, we report that treatment efficacy had a clear impact on the population dynamics: sufficient drug pressure bore a clear signature of purifying selection leading to apparent genetic stability. In contrast, <em>M. tuberculosis</em> populations subject to less drug pressure showed markedly different dynamics, including cases of acquisition of additional drug resistance.</p> <p><strong>Conclusions:</strong></p> <p>Our findings show that for a pathogen like <em>M. tuberculosis</em>, which is well adapted to the human host, purifying selection constrains the evolutionary trajectory to resistance in effectively treated individuals. Nonetheless, we also report a continuous turnover of minor variants, which could give rise to the emergence of drug resistance in cases of drug pressure weakening. Monitoring bacterial population dynamics could therefore provide an informative metric for assessing the efficacy of novel drug combinations.</p>
Figure 2 in Treatment of canine sarcoptic mange with afoxolaner (NexGard ) and afoxolaner plus milbemycin oxime (NexGard Spectra ) chewable tablets: efficacy under field conditions in Portugal and Germany
Figure 2. Dog with sarcoptic mange pre-treatment (first row pictures), and one month (second row pictures) and two months (third row pictures) after initiation of treatment with NexGard Spectra®.
Figure 1 in Treatment of canine sarcoptic mange with afoxolaner (NexGard ) and afoxolaner plus milbemycin oxime (NexGard Spectra ) chewable tablets: efficacy under field conditions in Portugal and Germany
Figure 1. Dog with sarcoptic mange pre-treatment (first row pictures), and one month (second row pictures) and two months (third row pictures) after initiation of treatment with NexGard®.
Figure 2 in Efficacy of low-dose EarthTec QZ treatment for the control of New Zealand mud snails Potamopyrgus antipodarum in a hatchery environment
Figure 2. Mean percent of active individuals with standard error (SE) plotted against days of treatment for three species of snail at Page Springs Hatchery.
Fig. 3. Predicted relationship between pre-treatment H in Age affects antibody levels and anthelmintic treatment efficacy in a wild rodent
Fig. 3. Predicted relationship between pre-treatment H. polygyrus burden and post-treatment H. polygyrus-specific IgG1 titre for A) juvenile mice, B) young adult mice and C) adult mice. ELW was split into equal thirds to group mice into juvenile (9.2 μg-15.8 μg), young adult (15.8 μg-22.4 μg) or adult mice (22.4 μg- 29.0 μg).
Fig. 1 in Age affects antibody levels and anthelmintic treatment efficacy in a wild rodent
Fig. 1. Dynamics of A) H. polygyrus burden, B) E. hungaryensis burden, C) total faecal IgA and D) H. polygyrus-specific IgG1 over the experimental period as predicted by minimal GAMM models. Red lines represent model estimates for animals treated with anthelmintic, black lines represent model estimates for control animals. Shaded areas represent estimated standard errors.
Fig. 2 in Age affects antibody levels and anthelmintic treatment efficacy in a wild rodent
Fig. 2. Relationship between mouse age (scaled ELW), treatment and post-treatment H. polygyrus burden as predicted by GLM model. The red line represents model estimates for treated animals, black lines represent model estimates for control animals. Shaded areas represent estimated standard errors. Points represent raw data.
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
ClinicalTrials.gov study NCT02798211. IPD Sharing: UNDECIDED. Countries: 2. Publications: 1.
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
ClinicalTrials.gov study NCT05032157. IPD Sharing: YES. Countries: 18. Publications: 1.
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Anti
ClinicalTrials.gov study NCT03738215. IPD Sharing: YES. Countries: 7. Publications: 1.
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
ClinicalTrials.gov study NCT03627091. IPD Sharing: YES. Countries: 34. Publications: 1.
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
ClinicalTrials.gov study NCT01610336. IPD Sharing: YES. Countries: 14. Publications: 1.
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
ClinicalTrials.gov study NCT05030311. IPD Sharing: YES. Countries: 19. Publications: 1.
Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Ris
ClinicalTrials.gov study NCT05386680. IPD Sharing: YES. Countries: 9. Publications: 1.
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
ClinicalTrials.gov study NCT02106351. IPD Sharing: YES. Countries: 8. Publications: 2.
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
ClinicalTrials.gov study NCT03852498. IPD Sharing: YES. Countries: 6. Publications: 1.
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
ClinicalTrials.gov study NCT01160211. IPD Sharing: YES. Countries: 29. Publications: 2.
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatmen
ClinicalTrials.gov study NCT02931539. IPD Sharing: YES. Countries: 14. Publications: 6.
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
ClinicalTrials.gov study NCT02563067. IPD Sharing: UNDECIDED. Countries: 19. Publications: 1.
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
ClinicalTrials.gov study NCT04558918. IPD Sharing: YES. Countries: 12. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.